Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -16.25% is 68% above its 3-year average of -50.91%, near the high end of its 3-year range (-175.01%–9.21%).
As of the fiscal period ended Tuesday, June 30, 2026. 87.00% above its 12-month average of -125.05%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -16.25%.
RETURN ON EQUITY (ROE)
-16.25%
RETURN ON EQUITY (ROE) AVG TTM
-125.05%
RETURN ON EQUITY (ROE) AVG 3Y
-59.88%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+87.00%
CURRENT VS 3Y AVG
+72.86%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
11.20%
median of 94 covered companies
CURRENT VS SECTOR MEDIAN
-245.12%
vs the sector median at left
Fortrea Holdings Inc.
Market Cap
$1.90B
Return on Equity (ROE)
-16.25%
TTM Avg
-125.05%
3Y Avg
-59.88%
5Y Avg
N/A
Market Cap
$1.74B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.71B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$2.16B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.52B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.76B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$1.00B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$474.59M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$458.62M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | $1.90B | -16.25% | -125.05% | -59.88% | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | -40.41% | -45.75% | -30.11% | -18.95% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -54.96% | -60.50% | -51.30% | -42.73% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -56.71% | -50.91% | -55.48% | -35.68% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -8.00% | -28.91% | -27.68% | -39.13% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 29.28% | 27.86% | 4.54% | -12.45% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -13.54% | -40.81% | -170.75% | -114.78% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | -6.60% | -10.82% | -11.36% | -7.59% |
| NRC Health (NRC)vs › | $458.62M | 89.43% | 81.07% | 67.39% | 61.90% |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | -28.18% | -0.06% | 10.58% | 10.58% |
ROE
-16.3%
ROA
-3.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -16.25% |
| 2026-03-31 | -84.98% |
| 2025-12-31 | -175.01% |
| 2025-09-30 | -174.74% |
| 2025-06-30 | -174.29% |
| 2025-03-31 | -92.04% |
| 2024-12-31 | -24.11% |
| 2024-09-30 | -20.04% |
| 2024-06-30 | -19.81% |
| 2024-03-31 | -7.55% |
| 2023-12-31 | -0.39% |
| 2023-09-30 | 3.31% |
| 2023-06-30 | 7.46% |
| 2023-03-31 | 9.21% |
| 2022-12-31 | 5.57% |
